Literature DB >> 1171096

Studies on a pyrimidine phosphoribosyltransferase from murine leukemia P1534J. Partial purification, substrate specificity, and evidence for its existence as a bifunctional complex with orotidine 5-phosphate decarboxylase.

P Reyes, M E Guganig.   

Abstract

A pyrimidine phosphoribosyltransferase, previously shown to utilize 5-fluorouracil and possibly also uracil and orotate (Reyes, P. (1969) Biochemistry 8, 2057-2062), has been purified about 100-fold from murine leukemia P1534J. Roughly 20% of the original activity was recovered to yield an enzyme preparation with a specific activity of 7.4 mumol of 5-fluorouracil utilized/hour/mg of protein. Disc gel electrophoresis of this preparation revealed the presence of a major band of protein accompanied by several trace contaminants. Emphasis was placed on a study of the substrate specificity of this enzyme. 5-Fluorouracil, uracil, and orotate phosphoribosyltransferase activities purified in parallel during fractionation with ammonium sulfate and protamine sulfate and eluted together from columns of Sephadex tG-150 and DEAE-cellulose. The three phosphoribosyltransferase activities eluted from the Sephadex columns with an apparent molecular weight of 55,000 to 60,000. In spite of this coordinate fractionation, preferential losses of orotate activity were experienced during DEAE-cellulose chromatography. Orotate activity continued to behave in a unique manner under other conditions, such as during proteolytic digestion. In the latter case, however, all three activities responded in parallel when digestion took place in the presence of 5mM UMP. The following results provided additional evidence to support the view that all three phosphoribosyltransferase activities may be catalyzed by the same enzyme: (a) the apparent Km for 5-phosphoribosyl 1-pyrophosphate (PP-ribose-P) did not change significantly when enzyme activity was measured with either 5-fluorouracil, uracil, or orotate; (b) 5-fluorouracil and uracil were found to be mutually competitive inhibitors; the effect of 5-fluorouracil on orotate activity was likewise competitive in nature; (c) in the absence of UMP, orotate was a noncompetitive inhibitor of 5-fluorouracil and uracil activities, but in the presence of 5mM UMP it became a competitive inhibitor of both of these activities; (d) 5-fluorouracil and orotate activities co-sedimented in 5 to 20% sucrose gradients (uracil activity was not examined); and (e) a wide variety of normal mouse tissues displayed virtually the same 5-fluorouracil to uracil to orotate activity ratio as found in P1534J enzyme preparations. The apparent Km and Ki values reported in this study indicate that the preferred pyrimidine substrate is orotate. It seems likely, therefore, that this enzyme functions in vivo as an orotate phosphoribosyltransferase. Orotate phosphoribosyltransferase and orotidine 5'-monophosphate (OMP) decarboxylase activities (a) eluted together during gel filtration on Sephadex G-150, (b) co-sedimented in 5 to 20% sucrose gradients, (c) remained associated during fractionation with ammonium sulfate and protamine sulfate, and (d) separated into a phosphoribosyltransferase and decarboxylase component when enzyme preparations previously subjected to limited proteolysis by elastase were sedimented in sucrose gradients...

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1171096

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.

Authors:  Maria Elena Meza-Avina; Lianhu Wei; Yan Liu; Ewa Poduch; Angelica M Bello; Ram K Mishra; Emil F Pai; Lakshmi P Kotra
Journal:  Bioorg Med Chem       Date:  2010-04-09       Impact factor: 3.641

2.  Novel interactions of fluorinated nucleotide derivatives targeting orotidine 5'-monophosphate decarboxylase.

Authors:  Melissa Lewis; Maria Elena Meza-Avina; Lianhu Wei; Ian E Crandall; Angelica Mara Bello; Ewa Poduch; Yan Liu; Christopher J Paige; Kevin C Kain; Emil F Pai; Lakshmi P Kotra
Journal:  J Med Chem       Date:  2011-03-21       Impact factor: 7.446

3.  Uracil phosphoribosyl transferase activity of mycoplasma and infected cell cultures.

Authors:  C W Long; R DelGiudice; R S Gardella; M Hatanaka
Journal:  In Vitro       Date:  1977-07

4.  Characterisation of a partially purified uracil phosphoribosyltransferase from the opportunistic pathogen Candida albicans.

Authors:  H M Alloush; D Kerridge
Journal:  Mycopathologia       Date:  1994-03       Impact factor: 2.574

5.  Bioorthogonal Metabolic Labeling of Nascent RNA in Neurons Improves the Sensitivity of Transcriptome-Wide Profiling.

Authors:  Esmi L Zajaczkowski; Qiong-Yi Zhao; Zong Hong Zhang; Xiang Li; Wei Wei; Paul R Marshall; Laura J Leighton; Sarah Nainar; Chao Feng; Robert C Spitale; Timothy W Bredy
Journal:  ACS Chem Neurosci       Date:  2018-06-15       Impact factor: 4.418

6.  A DNA sequence from Dictyostelium discoideum complements ura3 and ura5 mutations of Saccharomyces cerevisiae.

Authors:  E Boy-Marcotte; F Vilaine; J Camonis; M Jacquet
Journal:  Mol Gen Genet       Date:  1984

7.  5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.

Authors:  Y Maehara; Y Sakaguchi; I Takahashi; M Yoshida; H Kusumoto; H Masuda; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Molecular cloning and nucleotide sequence for the complete coding region of human UMP synthase.

Authors:  D P Suttle; B Y Bugg; J K Winkler; J J Kanalas
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Effect on liver tumor growth in rats of allopurinol and 5-fluorouracil in combination with hepatic artery ligation.

Authors:  G Carlsson; B Gustavsson; L Hafström
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.

Authors:  C Benz; M Schoenberg; M Choti; E Cadman
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.